Follow up care for liver cancer patients

Share This Post

The end of active treatment does not mean the end of care for liver cancer patients. Follow-up care includes continuing to regularly check the physical condition of the liver cancer patient to ensure that the cancer has not recurred, manage the side effects of the treatment, and monitor the patient’s overall health at any time. One of the most important goals of follow-up care is to check for recurrence. But a small percentage of cancer cells are likely to survive in the body but are difficult to find.

During follow-up care, the doctor may ask specific questions about the patient’s health. Some patients may require blood tests or imaging tests, depending on several factors, including the type of cancer and stage of the disease, and the type of treatment given.

During follow-up care, it can put pressure on liver cancer patients or family members. Most liver cancer patients may have long-term side effects, which may have a certain impact on the body and mood of liver cancer patients. Depending on the type of cancer, individual treatment plan and overall health status, patients and their families should communicate with doctors about the risks of such side effects, and it is extremely important to develop an appropriate survival care plan after the treatment is completed.

Nursing personnel play an important role in caring for patients with liver cancer. Nursing personnel’s responsibilities include: providing spiritual support and encouragement to patients; coordinating medical appointments, handling insurance and payment issues; assisting with meals, medication, and assistance Do housework, etc. Consult a doctor about possible side effects, including: what are the most likely side effects, what can be done to prevent or relieve the patient’s symptoms, etc.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy